
Epizyme EPZM
Quarterly report 2022-Q2
added 08-09-2022
Epizyme General and Administrative Expenses 2011-2025 | EPZM
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 125 M | 68.3 M | 44 M | 37.2 M | 28.4 M | 23.9 M | 20.9 M | 14 M | 7.51 M | 5 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 134 M | 5 M | 46.2 M |
Quarterly General and Administrative Expenses Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 24.1 M | 27.2 M | - | 32.8 M | 33.9 M | 36.4 M | 35 M | 30.6 M | 32.7 M | 26.9 M | 23.5 M | 17.1 M | 15.7 M | 12 M | 12.2 M | 11.5 M | 10.9 M | 9.36 M | 8.43 M | 9.31 M | 11.2 M | 8.27 M | 7.58 M | 7.52 M | 7.42 M | 5.85 M | 6.02 M | 6.68 M | 5.97 M | 5.24 M | 4.94 M | 5.67 M | 5.31 M | 4.96 M | 4.38 M | 3.59 M | 3.08 M | 3 M | 2.33 M | 1.63 M | 1.64 M | 1.91 M | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 36.4 M | 1.63 M | 12.8 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
ARCA biopharma
ABIO
|
13.1 M | - | 1052.0 % | $ 415 M | ||
|
Alpine Immune Sciences
ALPN
|
18 M | - | - | $ 2.17 B | ||
|
Amphastar Pharmaceuticals
AMPH
|
56.7 M | $ 25.37 | -2.07 % | $ 1.23 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
22.5 M | $ 4.75 | 1.61 % | $ 788 M | ||
|
Aclaris Therapeutics
ACRS
|
22.2 M | $ 3.28 | -2.53 % | $ 254 M | ||
|
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | ||
|
Acasti Pharma
ACST
|
7.17 M | - | 4.01 % | $ 150 M | ||
|
Adaptimmune Therapeutics plc
ADAP
|
73.5 M | - | -15.15 % | $ 60.3 M | ||
|
Ampio Pharmaceuticals
AMPE
|
7.08 M | - | -11.43 % | $ 502 K | ||
|
Aeglea BioTherapeutics
AGLE
|
45.8 M | - | - | $ 1.01 B | ||
|
Ascendis Pharma A/S
ASND
|
160 M | $ 210.49 | 0.16 % | $ 5 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Aptorum Group Limited
APM
|
5.41 M | $ 1.31 | -1.88 % | $ 7.14 M | ||
|
Alterity Therapeutics Limited
ATHE
|
5.51 M | $ 3.34 | -2.47 % | $ 8.04 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Anika Therapeutics
ANIK
|
95.8 M | $ 9.56 | 0.75 % | $ 140 M | ||
|
Brickell Biotech
BBI
|
11.2 M | - | -5.38 % | $ 6.06 M | ||
|
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B | ||
|
Bellicum Pharmaceuticals
BLCM
|
5.72 M | - | -9.72 % | $ 5.89 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
Aytu BioScience
AYTU
|
17.4 M | $ 2.35 | 3.07 % | $ 14.8 M | ||
|
Arena Pharmaceuticals
ARNA
|
126 M | - | -6.81 % | $ 3.04 B | ||
|
AstraZeneca PLC
AZN
|
15.2 B | $ 89.88 | -0.46 % | $ 96.9 B | ||
|
Baudax Bio
BXRX
|
24.1 M | - | 0.59 % | $ 63 K | ||
|
Avenue Therapeutics
ATXI
|
4.64 M | - | -52.27 % | $ 4.45 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
ChromaDex Corporation
CDXC
|
18.4 M | - | -0.88 % | $ 598 M | ||
|
Axon Enterprise
AXON
|
741 M | $ 568.3 | -2.19 % | $ 43 B | ||
|
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
12.1 M | - | -16.75 % | $ 25.8 M | ||
|
Clovis Oncology
CLVS
|
128 M | - | -7.23 % | $ 13 M | ||
|
Biogen
BIIB
|
2.4 B | $ 174.78 | 1.32 % | $ 25.4 B | ||
|
BioVie
BIVI
|
8.57 M | $ 1.46 | -3.31 % | $ 2.16 M | ||
|
Cortexyme
CRTX
|
17.7 M | - | -1.05 % | $ 67.1 M | ||
|
Benitec Biopharma
BNTC
|
6.97 M | $ 12.34 | -4.78 % | $ 508 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
136 M | - | - | $ 2.18 B | ||
|
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
714 M | $ 11.5 | 0.52 % | $ 744 M | ||
|
BioNTech SE
BNTX
|
286 M | $ 94.85 | -1.2 % | $ 27.2 B | ||
|
Eloxx Pharmaceuticals
ELOX
|
10.7 M | - | -5.68 % | $ 8.28 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.05 M | $ 0.28 | -2.28 % | $ 609 M | ||
|
Catalyst Biosciences
CBIO
|
14.7 M | $ 14.62 | -4.54 % | $ 962 M | ||
|
Acer Therapeutics
ACER
|
12.7 M | - | 2.71 % | $ 14 M | ||
|
Cerus Corporation
CERS
|
75.9 M | $ 2.17 | 0.7 % | $ 401 M | ||
|
Enochian Biosciences
ENOB
|
17.9 M | - | - | $ 40.5 M | ||
|
Acorda Therapeutics
ACOR
|
89.7 M | - | -24.86 % | $ 820 K | ||
|
Applied Molecular Transport
AMTI
|
37.4 M | - | - | $ 10.1 M | ||
|
Burford Capital Limited
BUR
|
99.3 M | $ 9.15 | 0.16 % | $ 1.5 B |